Autopsy report · NCT00418093
Oxaliplatin, Gemcitabine and Bevacizumab in Women With Recurrent Mullerian Carcinoma
Cause of deathOther
“THe study was terminated early due to a lack of accural”
Life of this trial
- Registered 4 months after it had already started.
- Ran for about 5 years 1 month before it stopped.
- 19 participants enrolled.
- Results were posted on the registry 2 years 8 months after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- Dana-Farber Cancer Institute
- Sponsor type
- University, hospital or other
- Conditions
- Ovarian Cancer; Fallopian Tube Cancer; Primary Peritoneal Cancer
- Interventions
- Gemcitabine; Oxaliplatin; Bevacizumab
- Participants
- 19
- Sites
- 2
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.